Samrat Pharmachem Limited (530125) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Samrat Pharmachem Limited ₹364, price ₹233, upside +56.2%, quality 50 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Samrat Pharmachem Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹182.83 – ₹1,193 · fair‑value band ₹218.97 – ₹598.34 · the ₹232.85 price screens below the ₹363.64 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Samrat Pharmachem in your weekly email
Every Wednesday you see whether Samrat Pharmachem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers iodine salts and bromines salts, as well as iodine derivatives for industries, such as pharmaceuticals, chemicals, food, fertilizers, salt, etc. The company also exports its products worldwide.
Show more
Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers iodine salts and bromines salts, as well as iodine derivatives for industries, such as pharmaceuticals, chemicals, food, fertilizers, salt, etc. The company also exports its products worldwide. Samrat Pharmachem Limited was founded in 1992 and is based in Mumbai, India.
Stock analysis
Samrat Pharmachem Limited (530125) currently trades at ₹232.85, while our model-based Fair Value estimate is ₹363.64, implying the stock looks roughly 36.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹415.75 per share, and 6 of the 9 models we run sit above the ₹232.85 price.
Bear case: the Asset-Based group reads lowest at ₹147.85, and 3 of the 9 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹218.97 (bear) to ₹598.34 (bull), the price of ₹232.85 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (below-average quality), in the Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Samrat Pharmachem Limited reported revenue of ₹2.9B in FY2026 versus ₹2.2B in FY2022, a compound +6.9%/yr. Reported net income was −₹33.1M in FY2026.
Key figures
Market cap ₹355M (≈ $3.7M) · P/E ratio 7.0 · P/S ratio 0.26 · EPS (TTM) ₹10.24 · Dividend yield 0.9% · Net margin −1.1% · Return on assets (EBIT) 11.0% · Operating margin 4.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 19% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Materials peers we cover trades at −39% fair-value upside, at 56%, 530125 screens cheaper than that median.
Fair Value models
Bear ₹218.97Fair Value ₹363.64Bull ₹598.34
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹5.22 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Start year 2021 (pandemic). Over 10 years: +16.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.6% (2021) → −1.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +3.2% a year for the price.
Compare Samrat Pharmachem Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 679 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+56.2% · Top 25%
Profitability
Return on assets0.0% · Bottom 25%
Net margin (TTM)2.3% · Below median
Operating margin (TTM)4.1% · Below median
Growth and dividend
Revenue growth−0.7% · Below median
Dividend yield (TTM)0.9% · Below median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Samrat Pharmachem Limited (530125) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹363.64 versus a price of ₹232.85, about +56% upside (undervalued).
What is the fair value of 530125?
Our model-based fair value for Samrat Pharmachem Limited is ₹363.64 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹232.85.
What is the quality score of 530125?
Samrat Pharmachem Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Samrat Pharmachem Limited (530125)?
Our model-based price target is the fair value of ₹363.64 (as of Sep 27, 2026) from 9 valuation models. Cautious scenario ₹218.97, optimistic scenario ₹598.34. It is a calculation from audited fundamentals, not an analyst target.
What is the Samrat Pharmachem Limited stock forecast for 2026?
Our models put fair value at ₹363.64, about +56% upside versus a price of ₹232.85 (undervalued). Cautious scenario ₹218.97, optimistic scenario ₹598.34. The calculation is refreshed regularly with new filings.
What is the revenue of Samrat Pharmachem Limited (530125)?
Samrat Pharmachem Limited reported trailing-twelve-month revenue of about ₹1.4B (latest available figure, as of Sep 27, 2026).
Does Samrat Pharmachem Limited pay a dividend?
Samrat Pharmachem Limited currently shows a dividend yield of about 0.87% relative to its recent price (as of Sep 27, 2026).
What growth is priced into Samrat Pharmachem Limited (530125)?
For today's price to be fair in a discounted-cash-flow model, Samrat Pharmachem Limited would have to grow free cash flow by +7.5 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.1 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 530125 use?
Our models discount Samrat Pharmachem Limited at 11.6 %: a base by market capitalisation (nano), damped by beta 0.75, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Samrat Pharmachem Limited that is +7.5 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Samrat Pharmachem Limited (530125) delivered so far?
Over the past 5 years revenue at Samrat Pharmachem Limited grew +10.1 % a year. The price currently implies +7.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Samrat Pharmachem Limited (530125) growing?
The median revenue growth in the sector is +8.1 % a year. That is the yardstick for the growth priced into Samrat Pharmachem Limited (+7.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Samrat Pharmachem Limited (530125)?
The free-cash-flow yield on the price is 8.04 %: that much free cash flow Samrat Pharmachem Limited produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Samrat Pharmachem Limited (530125)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Samrat Pharmachem Limited it is ₹363.64 per share (as of Sep 27, 2026), against a price of ₹232.85. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Samrat Pharmachem Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 530125 trades below its calculated fair value: price ₹232.85, fair value ₹363.64, a gap of about +56% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 530125?
No. The price is what the market pays today (₹232.85); the fair value is what the company's own numbers justify (₹363.64). For Samrat Pharmachem Limited the two are ₹130.79 per share apart. That gap is exactly why we show both numbers side by side.
How much is Samrat Pharmachem Limited worth?
The market values Samrat Pharmachem Limited at about ₹355M (market capitalisation, as of Sep 27, 2026). Per share that is ₹232.85; our models calculate a fair value of ₹363.64 per share.
What do the bullish and bearish scenarios say about 530125?
Our models span a range for Samrat Pharmachem Limited: cautious scenario ₹218.97, base ₹363.64, optimistic ₹598.34 per share (as of Sep 27, 2026, price ₹232.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 530125?
Samrat Pharmachem Limited trades at a price-to-earnings ratio of 7.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹363.64 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.3, EV/EBITDA 4.9.
How far is 530125 from its 52-week high?
Samrat Pharmachem Limited trades at ₹232.85, about 27% below its 52-week high of ₹317.45 and 19% above the low of ₹194.95 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹363.64 is for.
Which stocks are comparable to Samrat Pharmachem Limited?
From the same area (Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Samrat Pharmachem Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹232.85, calculated fair value ₹363.64 (+56%), Quality Score 50/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 530125 calculated?
We run Samrat Pharmachem Limited through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹363.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Samrat Pharmachem Limited currently trades 36 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Samrat Pharmachem Limited (530125)?
The closing price on Oct 1, 2026 was ₹232.85. Our model-based fair value is ₹363.64, about +56% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Samrat Pharmachem Limited right now?
The model range is unusually wide (₹218.97 to ₹598.34). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Samrat Pharmachem Limited
How large is the market capitalisation of Samrat Pharmachem Limited (530125)?
The market capitalisation of Samrat Pharmachem Limited is ₹355M (≈ $3.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Samrat Pharmachem Limited (530125)?
The price-to-sales ratio of Samrat Pharmachem Limited is 0.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Samrat Pharmachem Limited (530125)?
Earnings per share at Samrat Pharmachem Limited are ₹10.24 (price ÷ EPS = P/E 7.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Samrat Pharmachem Limited (530125)?
The dividend yield of Samrat Pharmachem Limited is 0.9% (payout 19.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Samrat Pharmachem Limited (530125)?
The net margin of Samrat Pharmachem Limited is −1.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Samrat Pharmachem Limited (530125)?
On an EBIT basis the return on assets of Samrat Pharmachem Limited is 11.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Samrat Pharmachem Limited (530125)?
The operating margin of Samrat Pharmachem Limited is 4.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Samrat Pharmachem Limited (530125)?
Revenue at Samrat Pharmachem Limited is growing −0.7% versus a year earlier (3y avg −2.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Samrat Pharmachem Limited (530125)?
Earnings per share at Samrat Pharmachem Limited are growing −57.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Samrat Pharmachem Limited (530125) carry?
The net debt of Samrat Pharmachem Limited is ₹48.2M (fiscal year 2026, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Samrat Pharmachem Limited in the live analysis
One click puts Samrat Pharmachem Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
